Everolimus in patients with severe pulmonary hypertension: A safety and efficacy pilot trial

Pulmonary Circulation

Volumn 3, Issue 3, 2013, Pages 632-638

  Seyfarth, Hans Jürgen ^a   Hammerschmidt, Stefan ^a   Halank, Michael ^b   Neuhaus, Petra ^a   Wirtz, Hubert R ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Exercise; Hemodynamic; MTOR inhibitor; Pulmonary hypertension; Treatment

Indexed keywords

EID: 84929512343     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.1086/674311     Document Type: Article

References (23)

1. D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991;115:343-349.
2. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006;129: 746-752.
3. Hoeper MM, Mayer E, Simonneau G, Rubin LJ. Chronic thromboembolic pulmonary hypertension. Circulation 2006; 113:2011-2020.
4. Seyfarth HJ, Halank M, Wilkens H, Schaefers HJ, Ewert R, Riedel M, Schuster E, Pankau H, Hammerschmidt S, Wirtz H. Standard PAH therapy improves long term survival in CTEPH patients. Clin Res Cardiol 2010;99:553-556.
5. Kunieda T, Nakanishi N, Satoh T, Kyotani S, Okano Y, Nagaya N. Prognosis of primary pulmonary hypertension and chronic majorvessel thromboembolic pulmonary hypertension determined from cumulative survival curves. Intern Med 1999;38: 543-546.
6. Le Pavec J, Souza R, Herve P, Lebrec D, Savale L, Tcherakian C, Jais X, et al. Portopulmonary hypertension. Am J Respir Crit Care Med 2008;178:637-643.
7. Le Pavec J, Humbert M, Mouthon L, Hassoun PM. Systemic sclerosis-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2010;181:1285-1293.
8. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009;30:2493-2537.
9. Barst R, Gibbs JSR, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, Sitbon O, Tapson VF, Galie N. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(suppl 1):S78-S84.
10. Dewachter L, Dewachter C, Naeije R. New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation. Expert Opin Investig Drugs 2010;19:469-488.
11. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005;353:1412-1413.
12. Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, Shapiro S, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010;182:1171-1177.
13. Hoeper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Galie N, Gómez-Sánchez MA, et al. Imatinib mesylate as addon therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013;127:1128-1138.
14. Klein M, Schermuly RT, Ellinghaus P, Milting H, Riedl B, Nikolova S, Pullamsetti SS, et al. Combined tyrosine and serine/ threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation 2008;118:2081-2090.
15. Nishimura T, Faul JL, Berry GJ, Veve I, Pearl RG, Kao PN. 40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med 2001;163:498-502.
16. Faul JL, Nishimura T, Berry GJ, Benson GV, Pearl RG, Kao PN. Triptolide attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med 2000;162:2252-2258.
17. Chapman TM, Perry CM. Everolimus. Drugs 2004;64:861-872.
18. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995;76:412-417.
19. Pinney SP, Mancini D. Cardiac allograft vasculopathy: advances in understanding its pathophysiology, prevention, and treatment. Curr Opin Cardiol 2004;19:170-176.
20. Kovarik JM. Everolimus: a proliferation signal inhibitor targeting primary causes of allograft dysfunction. Drugs Today 2004;40:101-109.
21. Vitko S, Tedesco H, Eris J, Pascual J, Whelchel J, Magee JC, Campbell S, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004;4:626-635.
22. Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA, Starling RC, et al.; RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003;349:847-858.
23. Vitko S, Margreiter R, Weimar W, Dantal J, Kuyper D, Winkler M, Øyen O, et al.; RAD B201 Study Group. Threeyear efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005;5:2521-2530